"Oxidopamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
Concept/Terms
Oxidopamine- Oxidopamine
- 6-OHDA
- 6-Hydroxydopamine
- 6 Hydroxydopamine
Below are MeSH descriptors whose meaning is more general than "Oxidopamine".
Below are MeSH descriptors whose meaning is more specific than "Oxidopamine".
This graph shows the total number of publications written about "Oxidopamine" by people in Harvard Catalyst Profiles by year, and whether "Oxidopamine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 |
| 1993 | 0 | 2 | 2 |
| 1994 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 2 | 3 | 5 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 5 | 5 |
| 2001 | 2 | 4 | 6 |
| 2002 | 1 | 8 | 9 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 3 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 4 | 4 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
Below are the most recent publications written about "Oxidopamine" by people in Profiles.
-
Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1a by parkin as a mechanism of neuroprotection by carnosic acid. Phytomedicine. 2021 Jan; 80:153369.
-
Early transcranial direct current stimulation treatment exerts neuroprotective effects on 6-OHDA-induced Parkinsonism in rats. Brain Stimul. 2020 May - Jun; 13(3):655-663.
-
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. Exp Neurol. 2018 05; 303:95-107.
-
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. Neurobiol Dis. 2018 04; 112:136-148.
-
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia. Neurobiol Aging. 2018 01; 61:82-92.
-
Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease. Neurobiol Aging. 2017 10; 58:30-33.
-
Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice. Nat Neurosci. 2017 Jun; 20(6):815-823.
-
Disrupted brain metabolic connectivity in a 6-OHDA-induced mouse model of Parkinson's disease examined using persistent homology-based analysis. Sci Rep. 2016 09 21; 6:33875.
-
Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease. J Neurosci Res. 2017 03; 95(3):907-917.
-
Preventative treatment in an animal model of ADHD: Behavioral and biochemical effects of methylphenidate and its interactions with ovarian hormones in female rats. Eur Neuropsychopharmacol. 2016 09; 26(9):1496-1506.